JPWO2022240760A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022240760A5
JPWO2022240760A5 JP2023569638A JP2023569638A JPWO2022240760A5 JP WO2022240760 A5 JPWO2022240760 A5 JP WO2022240760A5 JP 2023569638 A JP2023569638 A JP 2023569638A JP 2023569638 A JP2023569638 A JP 2023569638A JP WO2022240760 A5 JPWO2022240760 A5 JP WO2022240760A5
Authority
JP
Japan
Prior art keywords
compound
disease
pkkkrkv
cyclo
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518476A5 (https=
JP2024518476A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/028357 external-priority patent/WO2022240760A2/en
Publication of JP2024518476A publication Critical patent/JP2024518476A/ja
Publication of JP2024518476A5 publication Critical patent/JP2024518476A5/ja
Publication of JPWO2022240760A5 publication Critical patent/JPWO2022240760A5/ja
Pending legal-status Critical Current

Links

JP2023569638A 2021-05-10 2022-05-09 mRNAスプライシングを調節するための組成物及び方法 Pending JP2024518476A (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202163186664P 2021-05-10 2021-05-10
US63/186,664 2021-05-10
US202163210882P 2021-06-15 2021-06-15
US202163210866P 2021-06-15 2021-06-15
US63/210,866 2021-06-15
US63/210,882 2021-06-15
US202163239671P 2021-09-01 2021-09-01
US63/239,671 2021-09-01
US202263298587P 2022-01-11 2022-01-11
US63/298,587 2022-01-11
US202263318201P 2022-03-09 2022-03-09
US63/318,201 2022-03-09
US202263321921P 2022-03-21 2022-03-21
US63/321,921 2022-03-21
US202263362295P 2022-03-31 2022-03-31
US63/362,295 2022-03-31
PCT/US2022/028357 WO2022240760A2 (en) 2021-05-10 2022-05-09 COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING

Publications (3)

Publication Number Publication Date
JP2024518476A JP2024518476A (ja) 2024-05-01
JP2024518476A5 JP2024518476A5 (https=) 2025-05-13
JPWO2022240760A5 true JPWO2022240760A5 (https=) 2025-05-13

Family

ID=81854690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569638A Pending JP2024518476A (ja) 2021-05-10 2022-05-09 mRNAスプライシングを調節するための組成物及び方法

Country Status (5)

Country Link
US (1) US20250051780A1 (https=)
EP (1) EP4337261A2 (https=)
JP (1) JP2024518476A (https=)
CA (1) CA3217463A1 (https=)
WO (1) WO2022240760A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12378267B2 (en) 2021-06-17 2025-08-05 Entrada Therapeutics, Inc. Synthesis of FMOC-protected morpholino monomers and oligomers
EP4522221A1 (en) * 2022-05-09 2025-03-19 Entrada Therapeutics, Inc. Compositions and methods for delivery of nucleic acid therapeutics
WO2025038901A1 (en) * 2023-08-17 2025-02-20 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
WO2025160364A2 (en) * 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Compositions and methods comprising small nuclear rna (snrna) for the treatment of pompe disease
WO2025262186A2 (en) * 2024-06-20 2025-12-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic oligonucleotides for treating diseases being associated with or caused by a missense, nonsense or in-frame indel mutation

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
AU637800B2 (en) 1989-08-31 1993-06-10 City Of Hope Chimeric dna-rna catalytic sequences
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
ATE269870T1 (de) 1989-10-24 2004-07-15 Isis Pharmaceuticals Inc 2'-modifizierte oligonukleotide
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (es) 1990-05-11 1998-08-01 Microprobe Corp Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
US6365730B1 (en) 1990-06-19 2002-04-02 Gene Shears Pty. Limited DNA-Armed ribozymes and minizymes
JP3257675B2 (ja) 1990-10-12 2002-02-18 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー.ファウ. 修飾リボザイム
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
EP0538194B1 (de) 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
EP0673559A1 (en) 1992-12-14 1995-09-27 Honeywell Inc. Motor system with individually controlled redundant windings
AU6449394A (en) 1993-03-30 1994-10-24 Sterling Winthrop Inc. Acyclic nucleoside analogs and oligonucleotide sequences containing them
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
EP1133317A1 (de) 1998-11-26 2001-09-19 Pentapharm AG Transportsystemkonjugate
CZ296576B6 (cs) 1999-02-12 2006-04-12 Sankyo Company Limited Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
EP1178999B1 (en) 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
JP4151751B2 (ja) 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
US6960648B2 (en) 2000-10-13 2005-11-01 Universite De Lausanne Intracellular delivery of biological effectors
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
US7523096B2 (en) 2003-12-03 2009-04-21 Google Inc. Methods and systems for personalized network searching
AU2005252663B2 (en) 2004-06-03 2011-07-07 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ, インコーポレーテッド 6−修飾された二環式核酸類似体
EP1986697B1 (en) 2006-02-17 2016-06-29 GE Healthcare Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
WO2008036841A2 (en) 2006-09-22 2008-03-27 Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
US20120225034A1 (en) 2010-09-02 2012-09-06 Universite De Mons Agents useful in treating facioscapulohumeral muscular dystrophy
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2013112156A1 (en) 2012-01-26 2013-08-01 Hewlett-Packard Development Company, L.P. Micro-scale pendulum
CA2894684A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
AU2013359262C1 (en) 2012-12-12 2021-05-13 Massachusetts Institute Of Technology CRISPR-Cas component systems, methods and compositions for sequence manipulation
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
CN105121648B (zh) 2012-12-12 2021-05-07 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20170182189A1 (en) * 2014-05-23 2017-06-29 Genzyme Corporation Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
US20180346531A1 (en) * 2015-09-15 2018-12-06 Regents Of The University Of California Compositions and methods for delivering biotherapeutics
JP6657520B2 (ja) 2016-02-03 2020-03-04 株式会社神戸製鋼所 タイヤ試験装置のタイヤ空気充填機構及びタイヤ空気充填方法
AU2017222653B2 (en) 2016-02-26 2023-06-01 Research Institute At Nationwide Children's Hospital Recombinant virus products and methods for inducing DUX4 exon skipping
KR20170130253A (ko) 2016-05-18 2017-11-28 에스케이텔레콤 주식회사 적응형 스트리밍 서비스 제공 방법 및 이를 위한 장치
US10265249B2 (en) 2016-09-29 2019-04-23 The Procter & Gamble Company Fibrous structures comprising glyceride copolymers
WO2018093990A1 (en) 2016-11-16 2018-05-24 The Regents Of The University Of California Inhibitors of crispr-cas9
KR20180102871A (ko) 2017-03-08 2018-09-18 엘지전자 주식회사 이동단말기 및 이동단말기의 차량 제어 방법
TW201945014A (zh) * 2018-02-22 2019-12-01 美商安卓達治療股份有限公司 用於治療粒線體性神經胃腸腦病變之組合物及方法
EP3829597A4 (en) * 2018-07-30 2022-05-18 Sarepta Therapeutics, Inc. TRIMER PEPTIDES FOR ANTISENSE ADMINISTRATION
US20230020092A1 (en) * 2019-12-19 2023-01-19 Entrada Therapeutics, Inc. Compositions for delivery of antisense compounds

Similar Documents

Publication Publication Date Title
US11236329B2 (en) Compound and method for treating myotonic dystrophy
US6727355B2 (en) Pharmaceutical composition for treatment of Duchenne muscular dystrophy
ES2551154T3 (es) Procedimiento para la eficiente omisión del exón (44) en distrofia muscular de Duchenne y medios asociados
US6653467B1 (en) Medicament for treatment of Duchenne muscular dystrophy
CN109996807B (zh) Scn9a反义寡核苷酸
TWI672314B (zh) 反義核酸
JP2023123491A5 (https=)
CN112040988A (zh) 修饰的aav衣壳多肽用于治疗肌肉疾病
TW202346591A (zh) 連結有載體胜肽的核酸
US20150141321A1 (en) Compound and method for treating myotonic dystrophy
US20240390508A1 (en) Human transferrin receptor binding peptide-drug conjugate
TW201018471A (en) Multiple exon skipping compositions for DMD
RU2739987C2 (ru) Множественные олигонуклеотидные фрагменты на пептидном носителе
WO2024086633A1 (en) Rnai agents for inhibiting expression of dm1 protein kinase (dmpk) compositions thereof, and methods of use
WO2021134026A2 (en) Compositions and methods for nucleic acid delivery
US20040072743A1 (en) Pharmaceutical composition of modified pna molecules
JPWO2022240760A5 (https=)
US20230265429A1 (en) Skeletal muscle delivery platforms and methods of use thereof
US9579394B2 (en) Polyanion nanocomplexes for therapeutic applications
US20120177594A1 (en) Polyion complex comprising phd2 expression inhibiting substance
CA3184043A1 (en) Mirna-485 inhibitor for huntington's disease
JPWO2023034818A5 (https=)
US20230131083A1 (en) Use of mirna-485 inhibitors for treating amyotrophic lateral sclerosis (als)
JPWO2022204093A5 (https=)
WO2002053574A2 (en) Modified pna molecules